Kontafarma China Holdings Ltd
01312
Company Profile
Business description
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs active pharmaceutical ingredients and API intermediates in the PRC, operating of fitness centres and provision of consultation services for fitness and health activities and operating of the franchise business for royalty fee income. The operating segments include the pharmaceutical business and the Fitness business. The majority of its revenue derives from the pharmaceutical business segment.
Contact
30 Harbour Road
Room 12A 09-20, 12th Floor, Sun Hung Kai Centre
Wanchai
Hong Kong
HKGT: +852 27316500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
688
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,963.50 | 29.20 | 0.33% |
| CAC 40 | 7,800.88 | 33.70 | -0.43% |
| DAX 40 | 23,970.36 | 247.14 | -1.02% |
| Dow JONES (US) | 44,837.56 | 64.36 | -0.14% |
| FTSE 100 | 9,081.44 | 38.87 | -0.43% |
| HKSE | 25,562.13 | 173.78 | 0.68% |
| NASDAQ | 21,178.58 | 70.27 | 0.33% |
| Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
| NZX 50 Index | 12,928.01 | 17.27 | 0.13% |
| S&P 500 | 6,389.77 | 1.13 | 0.02% |
| S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
| SSE Composite Index | 3,597.94 | 4.28 | 0.12% |